ArticleBioinformation2026
Comparison of salivary caspase-3 biomarker in peri-implantitis among type 2 diabetic patients.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostic biomarker-based methodologies have become the form of reliable non-invasive measures of diagnosis of peri-implant disorders at the earliest possible stage. Therefore, it is of interest to determine efficacy of salivary caspase-3 levels as a non-invasive biomarker of early peri-implantitis (PI) diagnosis in diabetic patients with type 2 diabetes. The number of participants was 36, which was separated into three groups. Group I- PI with the presence of the diabetes mellitus (DM + PI) and group II- PI without the diabetes mellitus (NDM + PI) and group III- periodontally healthy and no diabetes mellitus (NDM + PH). Each of the participants had unstimulated whole saliva (10 mL) collected. Centrifugation and Salivary caspase-3 levels quantification was done on samples by using a commercially available Human Caspase-3 enzyme-linked immunosorbent assay kit. The data obtained was statistically tested. Caspase-3 has the potential of being a non- invasive salivary biomarker in high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.